Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies
Sathish Gopalakrishnan,1 Daryl Tan1,2 1Department of Hematology, Singapore General Hospital, Singapore, Republic of Singapore; 2Raffles Cancer Center, Raffles Hospital, Singapore, Republic of Singapore Abstract: Although the clinical outcomes of patients with multiple myeloma has improved tremendous...
Enregistré dans:
Auteurs principaux: | Gopalakrishnan S, Tan D |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2013
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/73f7face19004ee9bc6bb0fa042fbaf2 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
par: Foteini Theodorakakou, et autres
Publié: (2021) -
HOW I TREAT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS?
par: María-Victoria Mateos
Publié: (2021) -
INSIGHTS INTO DIAGNOSIS AND MANAGEMENT OF ADVANCED MULTIPLE MYELOMA
par: Vasile Musteata, et autres
Publié: (2021) -
Profile of elotuzumab and its potential in the treatment of multiple myeloma
par: Liu YC, et autres
Publié: (2014) -
CASE REPORT: COEXISTENCE OF CELIAC DISEASE AND MULTIPLE MYELOMA
par: Filiz YAVASOGLU, et autres
Publié: (2021)